Warrant Exercise

bioAffinity Technologies (BIAF, BIAFW) secured financing through securities purchase agreements with investors, involving the sale of Series B Convertible Preferred Stock and warrants to purchase common stock in a private placement. They also reached a warrant exercise agreement, generating $253,000. These transactions aim to raise approximately $1.2 million for working capital and general corporate purposes, supporting the development and commercialization of their CyPath® Lung test, a non-invasive early lung cancer detection method with reported 92% sensitivity. WallachBeth Capital LLC acted as placement agent.

SenesTech, Inc. (SNES), a biotech company specializing in fertility control for pest management, announced the closing of a warrant exercise generating $6.3 million. The company issued new short-term warrants priced at $0.125, potentially yielding an additional $11.5 million if fully exercised. SenesTech intends to use the net proceeds for working capital and general corporate initiatives. Their flagship product, ContraPest®, is a registered contraceptive for rats, aiming for humane and ecologically-sound pest control.